Journal of Medicinal Chemistry
Article
(11) (a) Clarke, V. R.; Ballyk, B. A.; Hoo, K. H.; Mandelzys, A.;
Pellizzari, A.; Bath, C. P.; Thomas, J.; Sharpe, E. F.; Davies, C. H.;
Ornstein, P. L.; Schoepp, D. D.; Kamboj, R. K.; Collingridge, G. L.;
Lodge, D.; Bleakman, D. A hippocampal GluR5 kainate receptor
regulating inhibitory synaptic transmission. Nature 1997, 389, 599−
603. (b) Vignes, M.; Clarke, V. R.; Parry, M. J.; Bleakman, D.; Lodge,
D.; Ornstein, P. L.; Collingridge, G. L. The GluR5 subtype of kainate
receptor regulates excitatory synaptic transmission in areas CA1 and
CA3 of the rat hippocampus. Neuropharmacology 1998, 37, 1269−
1277. (c) Bortolotto, Z. A.; Clarke, V. R.; Delany, C. M.; Parry, M. C.;
Smolders, I.; Vignes, M.; Ho, K. H.; Miu, P.; Brinton, B. T.; Fantaske,
R.; Ogden, A.; Gates, M.; Ornstein, P. L.; Lodge, D.; Bleakman, D.;
Collingridge, G. L. Kainate receptors are involved in synaptic plasticity.
Nature 1999, 402, 297−301. (d) Filla, S. A.; Winter, M. A.; Johnson,
K. W.; Bleakman, D.; Bell, M. G.; Bleisch, T. J.; Castano, A. M.;
Clemens-Smith, A; Del Prado, M.; Dieckman, D. K.; Dominguez, E.;
Escribano, A.; Ho, K. H.; Hudziak, K. J.; Katofiasc, M. A.; Martinez-Perez,
J. A.; Mateo, A.; Mathes, B. M.; Mattiuz, E. L.; Ogden, A. M. L.; Phebus,
L. A.; Stack, D. R.; Stratford, R. E.; Ornstein, P. L. Ethyl (3S,4aR,6S,8aR)-
6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroisoquinoline-3-
carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active
in two animal models of acute migraine. J. Med. Chem. 2002, 45, 4383−
4386. (e) Dominguez, E.; Iyengar, S.; Shannon, H. E.; Bleakman, D.; Alt,
A.; Arnold, B. M.; Bell, M. G.; Bleisch, T. J.; Buckmaster, J. L.; Castano, A.
M.; Prado, M. D.; Escribano, A.; Filla, S. A.; Ho, K. H.; Hudziak, K. J.;
Jones, C. K.; Martinez-Perez, J. A.; Mateo, A.; Mathes, B. M.; Mattiuz, E.
L.; Ogden, A. M. L.; Simmons, R. M. A.; Stack, D. R.; Stratford, R. E.;
Winter, M. A.; Wu, Z.; Ornstein, P. L. Two prodrugs of potent and
selective GluR5 kainate receptor antagonists active in three animal models
of pain. J. Med. Chem. 2005, 48, 4200−4203. (f) Weiss, B.; Alt, A.;
Ogden, A. M.; Gates, M.; Dieckman, D. K.; Clemens-Smith, A.; Ho,
K. H.; Jarvie, K.; Rizkalla, G.; Wright, R. A.; Calligaro, D. O.; Schoepp, D.;
Mattiuz, E. L.; Stratford, R. E.; Johnson, B.; Salhoff, C.; Katofiasc, M.;
Phebus, L. A.; Schenck, K.; Cohen, M.; Filla, S. A.; Ornstein, P. L.;
Johnson, K. W.; Bleakman, D. Pharmacological characterization of the
competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195
in vitro and in vivo. J. Pharmacol. Exp. Ther. 2006, 318, 772−781.
(12) (a) O’Neill, M. J.; Bond, A.; Ornstein, P. L.; Ward, M. A.; Hicks,
C. A.; Hoo, K.; Bleakman, D.; Logde, D. Decahydroisoquinolines:
novel competitive AMPA/kainate antagonists with neuroprotective
effects in global cerebral ischaemia. Neuropharmacology 1998, 37,
1211−1222. (b) Simmons, R. M. A.; Li, D. L.; Hoo, K. H.; Deverill,
M.; Ornstein, P. L.; Iyengar, S. Kainate GluR5 receptor mediates the
nociceptive response to formalin in the rat. Neuropharmacology 1998,
37, 25−36. (c) O’Neill, M. J.; Bogaert, L.; Hicks, C. A.; Bond, A.;
Ward, M. A.; Ebinger, G.; Ornstein, P. L.; Michotte, Y.; Lodge, D.
LY377770, a novel iGluR5 kainate receptor antagonist with
neuroprotective effects in global and focal cerebral ischaemia.
Neuropharmacology 2000, 39, 1575−1588. (d) Smolders, I.;
Bortolotto, Z. A.; Clarke, V. R. J.; Warre, R.; Khan, G. M.; O’Neill,
M. J.; Ornstein, P. L.; Bleakman, D.; Ogden, A.; Weiss, B.; Stables,
J. P.; Ho, K. H.; Ebinger, G.; Collingridge, G. L.; Lodge, D.; Michotte,
Y. Antagonists of GLUK5-containing kainate receptors prevent
pilocarpine-induced limbic seizures. Nat. Neurosci. 2002, 5, 796−804.
(13) Perrais, D.; Pinheiro, P. S.; Jane, D. E.; Mulle, C. Antagonism of
recombinant and native GluR7-containing kainate receptors.
Neuropharmacology 2009, 56, 131−140.
potentiation; NMDA, N-methyl-D-aspartic acid; NMDAR,
N-methyl-D-aspartic acid receptor; PEI, polyethylenimine; PSNI,
partial saphenous nerve ligation injury; vF, Von Frey; WT, wild
type
REFERENCES
■
(1) (a) Watkins, J. C.; Jane, D. E. The glutamate story. Br. J.
Pharmacol. 2006, 147, S100−S108. (b) Kew, J. N. C.; Kemp, J. A.
Ionotropic and metabotropic glutamate receptor structure and
pharmacology. Psychopharmacology 2005, 179, 4−29. (c) Traynelis,
S. F.; Wollmuth, L. P.; McBain, C. J.; Menniti, F. S.; Vance, K. M.;
Ogden, K. K.; Hansen, K. B.; Yuan, H.; Myers, S. J.; Dingledine, R.
Glutamate receptor ion channels: structure, regulation, and function.
Pharmacol. Rev. 2010, 62, 405−496.
(2) (a) Collingridge, G. L.; Olsen, R. W.; Peters, J.; Spedding, M. A
nomenclature for ligand-gated ion channels. Neuropharmacology 2009,
56, 2−5. (b) Jane, D. E.; Lodge, D. L.; Collingridge, G. L. Kainate
receptors: pharmacology, function and therapeutic indications.
Neuropharmacology 2009, 56, 90−113.
(3) (a) Monaghan, D. T.; Jane, D. E. Pharmacology of the NMDA
Receptor. In Biology of the NMDA Receptor; VanDongen, A., Ed.;
Taylor and Francis: London, U.K., 2008; pp 257−282. (b) Neyton, J.;
Paoletti, P. Relating NMDA receptor function to receptor subunit
composition: limitations of the pharmacological approach. J. Neurosci.
2006, 26, 1331−1333.
(4) (a) Kalia, L. V.; Kalia, S. K.; Salter, M. W. NMDA receptors in
clinical neurology: excitatory times ahead. Lancet Neurol. 2008, 7,
742−755. (b) Hizue, M.; Pang, C. H.; Yokoyama, M. Involvement of
N-methyl-D-aspartate-type glutamate receptor epsilon I and epsilon 4
subunits in tonic inflammatory pain and neuropathic pain. NeuroReport
2005, 16, 1667−1670. (c) Sanacora., G.; Zarate, C. A.; Krystal, J. H.;
Manji, H. K. Targeting the glutamatergic system to develop novel,
improved therapeutics for mood disorders. Nat. Rev. Drug Discovery
2008, 7, 426−437.
(5) (a) Buller, A. L.; Monaghan, D. T. Pharmacological heterogeneity
of NMDA receptors: characterization of NR1a/NR2D heteromers
expressed in Xenopus oocytes. Eur. J. Pharmacol. 1997, 320, 87−94.
(b) Feng, B.; Tse, H. W.; Skifter, D. A.; Morley, R. M.; Jane, D. E.;
Monaghan, D. T. Structure−activity analysis of a novel NR2C/NR2D-
preferring NMDA receptor antagonist: 1-(phenanthrene-2-
carbonyl)piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol. 2004,
141, 508−516. (c) Costa, B. M.; Feng, B.; Tsintsadze, T. S.; Morley,
R. M.; Irvine, M. W.; Tsintsadze, V. P.; Lozovaya, N. A.; Jane, D. E.;
Monaghan, D. T. NMDA receptor NR2 subunit selectivity of a series
of novel piperazine-2,3-dicarboxylate derivatives; preferential blockade
of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1
synapse. J. Pharmacol. Exp. Ther. 2009, 331, 618−626.
(6) Morley, R. M.; Tse, H.-W.; Feng, B.; Miller, J. C.; Monaghan,
D. T.; Jane, D. E. Synthesis and pharmacology of N1-substituted
piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor
antagonists. J. Med. Chem. 2005, 48, 2627−2637.
(7) Fischer, G.; Mutel, V.; Trube, G.; Malherbe, P.; Kew, J. N.;
Mohacsi, E.; Heitz, M. P.; Kemp, J. A. Ro 25-6981, a highly potent and
selective blocker of N-methyl-D-aspartate receptors containing the
NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 1997,
283, 1285−1292.
(14) (a) Dolman, N. P.; Troop, H. M.; More, J. C. A.; Alt, A. J.;
Ogden, A. M.; Jones, S.; Morley, R. M.; Roberts, P. J.; Bleakman, D.;
Collingridge, G. L.; Jane, D. E. Synthesis and pharmacology of
willardiine derivatives acting as antagonists of kainate receptors. J. Med.
Chem. 2005, 48, 7867−7881. (b) Dolman, N. P.; More, J. C. A.; Alt,
A.; Ogden, A. M.; Troop, H. M.; Bleakman, D.; Collingridge, G. L.;
Jane, D. E. Structure−activity relationship studies on N3-substituted
willardiine derivatives acting as AMPA or kainate receptor antagonists.
J. Med. Chem. 2006, 49, 2579−2592.
(8) Costa, B. M.; Irvine, M. W.; Fang, G.; Eaves, R. J.; Mayo-Martin,
M. B.; Skifter, D. A.; Monaghan, D. T.; Jane, D. E. A novel family of
negative and positive allosteric modulators of NMDA receptors.
J. Pharmacol. Exp. Ther. 2010, 335, 614−621.
(9) Mosley, C. A.; Acker, T. M.; Hansen, K. B.; Mullasseril, P.;
Andersen, K. T.; Le, P.; Vellano, K. M.; Brauner-Osborne, H.; Liotta,
̈
D. C.; Traynelis, S. F. Quinazolin-4-one derivatives: a novel class of
noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate
receptor antagonists. J. Med. Chem. 2010, 53, 5476−5490.
(10) Sheardown, M.; Nielsen, E.; Hansen, A.; Jacobsen, P.; Honore,
T. 2,3-Dihydroxy-6-nitro-7-sulphamoyl-benzo(F)quinoxaline: a
neuroprotectant for cerebral ischemia. Science 1990, 247, 571−574.
(15) More, J. C. A.; Nistico, R.; Dolman, N. P.; Clarke, V. R. J.; Alt,
A. J.; Ogden, A. M.; Buelens, F. P.; Troop, H. M.; Kelland, E. E.; Pilato,
F.; Bleakman, D.; Bortolotto, Z. A.; Collingridge, G. L.; Jane, D. E.
340
dx.doi.org/10.1021/jm201230z | J. Med. Chem. 2012, 55, 327−341